One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia

[1]  H. Möller,et al.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.

[2]  A. Barker,et al.  Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community , 2016, Therapeutic advances in psychopharmacology.

[3]  John M. Davis,et al.  Dose Equivalents for Antipsychotic Drugs: The DDD Method. , 2016, Schizophrenia bulletin.

[4]  S. Leucht,et al.  Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. , 2016, JAMA psychiatry.

[5]  D. Faries,et al.  Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study , 2015, BMC Psychiatry.

[6]  D. MacInnes,et al.  A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates , 2015, International clinical psychopharmacology.

[7]  A. Tockhorn,et al.  Retrospective Database Study on Health Care Resource Utilization of Patients Initiating Long-Acting Olanzapine in Sweden. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  H. Detke,et al.  Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study , 2014, International clinical psychopharmacology.

[9]  P. Weiden,et al.  Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia , 2014, Journal of clinical psychopharmacology.

[10]  N. Hoertel,et al.  Poor longitudinal continuity of care is associated with an increased mortality rate among patients with mental disorders: Results from the French National Health Insurance Reimbursement Database , 2014, European Psychiatry.

[11]  J. Lauriello,et al.  How study designs influence comparative effectiveness outcomes: The case of oral versus long-acting injectable antipsychotic treatments for schizophrenia , 2014, Schizophrenia Research.

[12]  David Taylor,et al.  Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization , 2014, International clinical psychopharmacology.

[13]  C. Altar,et al.  The social and economic burden of treatment-resistant schizophrenia: a systematic literature review , 2014, International clinical psychopharmacology.

[14]  T. Kishimoto,et al.  Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. , 2013, The Journal of clinical psychiatry.

[15]  Taishiro Kishimoto,et al.  Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies , 2013, World psychiatry : official journal of the World Psychiatric Association.

[16]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[17]  T. Dilla,et al.  Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia , 2013, Patient preference and adherence.

[18]  Paul McCrone,et al.  A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. , 2012, Journal of psychiatric research.

[19]  J. Benichou,et al.  Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS) , 2012, Schizophrenia Research.

[20]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[21]  J. Tiihonen,et al.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.

[22]  T. Kishimoto,et al.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives , 2011, Dialogues in clinical neuroscience.

[23]  J. Kane,et al.  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. , 2010, The American journal of psychiatry.

[24]  W. Bobo,et al.  A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. , 2008, The Journal of clinical psychiatry.

[25]  J. Kane,et al.  Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. , 2007, The Journal of clinical psychiatry.

[26]  J. Lieberman,et al.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.

[27]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[28]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.

[29]  Christian R. Dolder,et al.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.

[30]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[31]  M. Mimura,et al.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. , 2014, Schizophrenia bulletin.

[32]  M. Lambert,et al.  Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management , 2014, CNS Drugs.

[33]  M. Knapp,et al.  The global costs of schizophrenia. , 2004, Schizophrenia bulletin.